Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial.
Ward R, Huang Z, Rockhold FW, Baumgartner I, Berger JS, Blomster JI, Fowkes FGR, Katona BG, Mahaffey KW, Norgren L, Vemulapalli S, Povsic TJ, Mehta R, Hiatt WR, Patel MR, Jones WS. Ward R, et al. Among authors: berger js. Am Heart J. 2020 Feb;220:51-58. doi: 10.1016/j.ahj.2019.11.007. Epub 2019 Nov 18. Am Heart J. 2020. PMID: 31783279 Clinical Trial.
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.
Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM, Topol EJ, Berger PB; CHARISMA Investigators. Berger JS, et al. Among authors: berger pb. Circulation. 2009 Dec 8;120(23):2337-44. doi: 10.1161/CIRCULATIONAHA.109.866533. Epub 2009 Nov 23. Circulation. 2009. PMID: 19933933 Free PMC article. Clinical Trial.
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW. Berger JS, et al. Am Heart J. 2009 Dec;158(6):998-1004.e1. doi: 10.1016/j.ahj.2009.10.010. Am Heart J. 2009. PMID: 19958867 Clinical Trial.
An aspirin a day: are we barking up the wrong willow tree?
Krantz MJ, Berger JS, Hiatt WR. Krantz MJ, et al. Among authors: berger js. Pharmacotherapy. 2010 Feb;30(2):115-8. doi: 10.1592/phco.30.2.115. Pharmacotherapy. 2010. PMID: 20099985 No abstract available.
Peripheral artery disease, biomarkers, and darapladib.
Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER 3rd. Berger JS, et al. Am Heart J. 2011 May;161(5):972-8. doi: 10.1016/j.ahj.2011.01.017. Am Heart J. 2011. PMID: 21570531 Free PMC article. Clinical Trial.
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger JS, Bhatt DL, Steg PG, Steinhubl SR, Montalescot G, Shao M, Hacke W, Fox KA, Berger PB, Topol EJ, Lincoff AM. Berger JS, et al. Among authors: berger pb. Am Heart J. 2011 Jul;162(1):98-105.e1. doi: 10.1016/j.ahj.2011.04.015. Am Heart J. 2011. PMID: 21742095 Clinical Trial.
407 results